Cardiovascular highlights from non-cardiology journals

Lindsay, Alistair; Contractor, Hussain
March 2011
Heart;Mar2011, Vol. 97 Issue 5, p435
Academic Journal
The article presents various medical abstracts related to cardiovascular disease including the risk of cardiovascular agent rofecoxib on patients after discontinuation, sensitivity of troponin in detecting subclinical cardiovascular disorder, and the role of microRNA in myocardial infarction.


Related Articles

  • CV events persist for one year after stopping Vioxx.  // Reactions Weekly;10/25/2008, Issue 1225, p1 

    This article discusses research being done on cardiovascular events associated with rofecoxib. It references a study by J. A. Baron et al., in the online edition of "Lancet" on October 14, 2008. The study showed an increase risk of myocardial infarction (MI), stroke and vascular death among...

  • Australian court finds Vioxx increased risk of heart attack. Moynihan, Ray // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/20/2010, Vol. 340 Issue 7747, p613 

    The article discusses a class action lawsuit concerning the anti-arthritis drug rofecoxib. The lawsuit, which was filed by approximately 600 Australians, alleges that the drug increases the risk of heart attack. Federal court judge Christopher Jessup ruled that rofecoxib contributed to the heart...

  • High-dose rofecoxib MI effects reversible. Baines, Emma // GP: General Practitioner;2/4/2005, p10 

    This article reports that patients on high-dose rofecoxib were at 73 percent increased risk of acute Myocardial Infraction (MI), according to another study highlighting the cardiovascular dangers of the withdrawn drug. The study found no increased risk of MI with celecoxib, the safety of which...

  • Cardiovascular AE risk not increased once off Vioxx.  // Reactions Weekly;5/20/2006, Issue 1102, p3 

    Presents the results of the preliminary analyses of the off-drug extension of the Adenomatous Polyp Prevention on Vioxx (APPROVe). Impact of rofecoxib, APPROVe on the risk of cardiovascular adverse event in patients who had previously received Vioxx; Myocardial infarction and stroke among...

  • Analysis in the Vioxx APPROVe trial corrected.  // Reactions Weekly;7/8/2006, Issue 1109, p1 

    The article reports that the "New England Journal of Medicine" has published a correction notice with regard to an analysis in Merck's Adenomatous Polyp Prevention on Vioxx study. In the original study, it was reported that compared with placebo recipients, rofecoxib recipients had an increased...

  • Is acute rofecoxib use associated with acute MI?  // Reactions Weekly;5/13/2006, Issue 1101, p3 

    The article presents a study by the researchers from Canada discussing the effects of a drug rofecoxib on elderly patients which results in increased risk of myocardial infarction (MI).

  • Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan: An Observational Study. Weng-Foung Huang; Fei-Yuan Hsiao; Yi-Wen Tsai; Yu-Wen Wen; Yaw-Tang Shih // Drug Safety;2006, Vol. 29 Issue 3, p261 

    BACKGROUND: Using national data (2001–2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam....

  • Acute myocardial infarction. McVeigh, James P.; Musto, Jennie // Australian Nursing Journal;Aug99, Vol. 7 Issue 2, supplement p1 

    Focuses on cardiovascular disease affecting the Australian population. Statistics on deaths associated with acute myocardial infarction (AMI); Information on myocardium; Significance of an understanding of the pathophysiology of acute coronary occlusion; Treatment of AMI.

  • Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972-7 in North Karelia. Salonen, Jukka T.; Puska, Pekka; Mustaniemi, Harri // British Medical Journal;11/10/1979, Vol. 2 Issue 6199, p1178 

    Examines the efficacy of the comprehensive community program in controlling cardiovascular diseases (CVD) in North Karelia, Finland. Efforts to reduce the mortality and morbidity associated with CVD; Decrease on the rate of mortality; Decline on the incidence of acute myocardial infarction;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics